Drugs / Neukoplast™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00900809 | May 2014 → Jun 2015 | acute myeloid leukemia | ImmunityBio, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neukoplast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00900809 ↗ |
| Known as | NK-92 | “Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia” NCT00900809 ↗ |
| Modality | Cell therapy | “Natural Killer Cell Line, Neukoplast™(NK-92)” NCT00900809 ↗ |
| Route | Intravenous | “The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes.” NCT00900809 ↗ |